Literature DB >> 16556696

Post-bronchodilator spirometry reference values in adults and implications for disease management.

Ane Johannessen1, Sverre Lehmann, Ernst R Omenaas, Geir Egil Eide, Per S Bakke, Amund Gulsvik.   

Abstract

RATIONALE: International guidelines promote the use of post-bronchodilator spirometry values in the definition and severity classification of chronic obstructive pulmonary disease. However, post-bronchodilator reference values have not yet been developed.
OBJECTIVES: To derive reference values for post-bronchodilator forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and FEV1/FVC, and to compare these reference values with locally derived and existing pre-bronchodilator reference values.
METHODS: Based on a random sample of a general adult population, 2,235 subjects (70% of invited subjects) performed spirometry with reversibility testing. A reference population of healthy never-smokers constituted 23% of the study population (n=515). Reference values for median and lower-limit-of-normal pre- and post-bronchodilator lung function and bronchodilator response were modeled using quantile regression analyses. MAIN
RESULTS: The reference population had equal proportions of men and women in the age range 26-82 yr. Both FEV1 and FVC decreased with age and increased with height. FEV1/FVC decreased with age, although this trend was not statistically significant for men after bronchodilatation. Linear models gave the best overall fit. Lower-limit-of-normal post-bronchodilator FEV1/FVC exceeded 0.7 for both sexes. Post-bronchodilator prediction equations gave higher predicted FEV1 and FEV1/FVC than both locally derived and existing pre-bronchodilator equations. The bronchodilator response decreased with age.
CONCLUSIONS: The present study is the first to develop reference values for post-bronchodilator lung function. Post-bronchodilator prediction equations can facilitate better management of patients with chronic obstructive pulmonary disease by avoiding falsely high FEV1% predicted with a subsequent underestimation of disease severity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16556696     DOI: 10.1164/rccm.200601-023OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  53 in total

1.  Early detection of COPD combined with individualized counselling for smoking cessation: a two-year prospective study.

Authors:  Tuula Toljamo; Marjo Kaukonen; Pentti Nieminen; Vuokko L Kinnula
Journal:  Scand J Prim Health Care       Date:  2010-03       Impact factor: 2.581

2.  What is the difference between FEV1 change in percentage predicted value and change over baseline in the assessment of bronchodilator responsiveness in patients with COPD?

Authors:  Wenhua Jian; Jinping Zheng; Yi Hu; Yin Li; Yi Gao; Jiaying An
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

Review 3.  Spirometry.

Authors:  Theodore G Liou; Richard E Kanner
Journal:  Clin Rev Allergy Immunol       Date:  2009-04-04       Impact factor: 8.667

4.  ARTP statement on pulmonary function testing 2020.

Authors:  Karl Peter Sylvester; Nigel Clayton; Ian Cliff; Michael Hepple; Adrian Kendrick; Jane Kirkby; Martin Miller; Alan Moore; Gerrard Francis Rafferty; Liam O'Reilly; Joanna Shakespeare; Laurie Smith; Trefor Watts; Martyn Bucknall; Keith Butterfield
Journal:  BMJ Open Respir Res       Date:  2020-07

5.  Gender differences in COPD: are women more susceptible to smoking effects than men?

Authors:  Inga-Cecilie Sørheim; Ane Johannessen; Amund Gulsvik; Per S Bakke; Edwin K Silverman; Dawn L DeMeo
Journal:  Thorax       Date:  2010-06       Impact factor: 9.139

6.  Do symptoms predict COPD in smokers?

Authors:  Jill A Ohar; Alireza Sadeghnejad; Deborah A Meyers; James F Donohue; Eugene R Bleecker
Journal:  Chest       Date:  2010-04-02       Impact factor: 9.410

7.  Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations.

Authors:  Dheeraj Gupta; Ritesh Agarwal; Ashutosh Nath Aggarwal; V N Maturu; Sahajal Dhooria; K T Prasad; Inderpaul S Sehgal; Lakshmikant B Yenge; Aditya Jindal; Navneet Singh; A G Ghoshal; G C Khilnani; J K Samaria; S N Gaur; D Behera
Journal:  Lung India       Date:  2013-07

8.  Present and future costs of COPD in Iceland and Norway: results from the BOLD study.

Authors:  R Nielsen; A Johannessen; B Benediktsdottir; T Gislason; A S Buist; A Gulsvik; S D Sullivan; T A Lee
Journal:  Eur Respir J       Date:  2009-04-08       Impact factor: 16.671

9.  Duration of salmeterol-induced bronchodilation in mechanically ventilated chronic obstructive pulmonary disease patients: a prospective clinical study.

Authors:  Polychronis Malliotakis; Manolis Linardakis; George Gavriilidis; Dimitris Georgopoulos
Journal:  Crit Care       Date:  2008-11-14       Impact factor: 9.097

10.  Comparison of the prevalence of chronic obstructive pulmonary disease diagnosed by lower limit of normal and fixed ratio criteria.

Authors:  Yong Il Hwang; Chang Hwan Kim; Hye-Ryun Kang; Taerim Shin; Sang Myeon Park; Seung Hun Jang; Yong Bum Park; Cheol Hong Kim; Dong-Gyu Kim; Myung Goo Lee; In-Gyu Hyun; Ki-Suck Jung
Journal:  J Korean Med Sci       Date:  2009-07-29       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.